Myopia (Nearsightedness)
Myopia is a chronic, progressive refractive error in which parallel light rays entering the eye in an unaccommodated state focus anterior to the photoreceptor layer of the retina, producing blurred distance vision while near tasks remain clear. Structured epidemiologic modelling shows that roughly 30 % of the global population is currently myopic, and meta-analytic projections indicate that, if unchecked, one in two humans will be myopic and one in ten highly myopic by mid-century, creating an unprecedented public-health burden of vision-threatening sequelae such as myopic maculopathy and retinal detachment.
Symptoms
Children typically complain of blurred school-board vision, squinting, eye strain and headaches, whereas adults note difficulty reading traffic signs or cinema subtitles. Progressive myopia may manifest as frequent prescription changes, night myopia, floaters, photopsias from peripheral lattice degeneration, or acute onset of flashes and curtain-like visual loss signalling retinal detachment.
Risk Factors
The strongest determinants are parental myopia (odds ratio ≈ 3 for one myopic parent and ≈ 6 for two), East-Asian ancestry, sustained high-level near work before age eight, fewer than two hours of bright outdoor light daily, premature birth with low birth weight, urban residency with high educational pressure, and chronically delayed circadian phase. Rapid progression is especially likely in children who present before age seven with ≥ −3 D spherical equivalent, have accommodative lag > 1.00 D, or exhibit peripheral retinal hyperopic shifts on aberrometry.
Diagnosis
Comprehensive cycloplegic refraction remains the reference standard: spherical equivalent ≤ −0.50 D confirms myopia, and ≥ −6 D defines high myopia. Axial length measurement by partial-coherence interferometry (> 26 mm is high-risk), peripheral refraction mapping, aberrometry, slit-lamp evaluation, mydriatic funduscopy for lattice or lacquer cracks, wide-field OCT for myopic maculopathy, and axial-length growth velocity plotting (< 0.10 mm year⁻¹ denotes stability) refine risk stratification and treatment targets.
Treatment
Conventional single-vision spectacles correct blur but do not halt axial elongation. Evidence-based myopia-control options include nightly orthokeratology lenses that flatten the central cornea and create peripheral myopic defocus; daily-wear dual-focus or extended-depth-of-focus soft contact lenses approved by the U.S. FDA in 2022; and contrast-modulating DOT spectacle lenses, recently granted. Pharmacologic therapy with ultra-low-dose atropine (0.01 %–0.05 %) instilled once nightly reduces annual axial elongation by 26 %–45 % with an excellent safety profile, although some randomised trials have reported minimal benefit at 0.01 % in European cohorts, prompting region-specific dose selection. Combination strategies—orthokeratology plus 0.01 % atropine or dual-focus lenses plus higher-dose atropine—are under investigation. Refractive surgery (LASIK, SMILE, phakic IOLs) corrects established myopia in adults with stable axial length but does not prevent future retinal complications.
Outlook
With contemporary control measures, axial-length velocity can be halved, delaying or averting sight-threatening high myopia. Untreated progressive myopia, however, raises lifetime risk of myopic macular degeneration twenty-fold and rhegmatogenous retinal detachment eight-fold, and high myopia is now the leading cause of irreversible blindness in parts of East Asia.
Complications
High myopia predisposes to posterior staphyloma, peripapillary choroidal atrophy, choroidal neovascularisation, myopic traction maculopathy, retinal-pigment-epithelium rips, foveoschisis, early-onset cataract, open-angle glaucoma with large optic-nerve tilt, and phakic IOL-related endothelial loss.
Prevention
Primary prevention emphasises prescriptive daily outdoor time in pre-schoolers, delayed introduction of intensive near work, classroom lighting exceeding 500 lux, and public-health policies that redesign urban schooling to incorporate outdoor curricula. Secondary prevention starts with annual screening of pre-school children and immediate initiation of optical or pharmacologic control once myopia is documented.
Support
Daily outdoor exposure of two to three hours in ≥ 10 000 lux daylight, the “20-20-2 rule” (every 20 minutes of near work look 20 feet away for 20 seconds and accumulate 2 hours outdoors), ergonomically positioned reading material at ≥ 30 cm, ambient lighting ≥ 500 lux during near tasks, and enforcing digital-device breaks slow progression. Parents should keep a “myopia diary” of axial length and refraction, administer atropine consistently at bedtime, and ensure adherence to contact-lens hygiene.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
